European Journal of Inorganic Chemistry, ISSN 1434-1948, 05/2011, Issue 14, pp. 2264 - 2272
Journal Article
Propellants, Explosives, Pyrotechnics, ISSN 0721-3115, 05/2019, Volume 44, Issue 5, pp. 579 - 587
The possibilities of the application of Data Science Methods in predicting certain macroscopic properties have been examined in energetic compounds. Artificial...
Data science | High energetic materials | Detonation velocity | Multifactor computational models | Knowledge Base Formatting | Artificial neural networks | ENGINEERING, CHEMICAL | IMPACT SENSITIVITY | CHNOFCL | CHEMISTRY, APPLIED | Explosives | Scientists | Neural networks | Analysis | Organic chemistry | Data points | Detonation | Predictions | Chemical composition
Data science | High energetic materials | Detonation velocity | Multifactor computational models | Knowledge Base Formatting | Artificial neural networks | ENGINEERING, CHEMICAL | IMPACT SENSITIVITY | CHNOFCL | CHEMISTRY, APPLIED | Explosives | Scientists | Neural networks | Analysis | Organic chemistry | Data points | Detonation | Predictions | Chemical composition
Journal Article
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, ISSN 1434-1948, 05/2011, Issue 14, pp. 2264 - 2272
The reaction of PCl3 with CyNH2 in a 1: 3 ratio afforded the dichloro-lambda(3)-cyclodiphosphazane, cis-[ClP(mu-NCy)](2) (2), whereas the corresponding 1: 5...
Heterocycles | Phosphorus | CRYSTAL-STRUCTURES | Chalcogens | PHOSPHAZANE OLIGOMERS | CHEMISTRY, INORGANIC & NUCLEAR | HETEROMETALLIC COMPLEXES | REVERSIBLE CONVERSION | Hydrogen bonds | TRANS ISOMERS | CYCLODIPHOSPHAZANE | MOLECULAR-STRUCTURES | Selenium | ETHENE POLYMERIZATION | 1ST STRUCTURAL-CHARACTERIZATION | SOLID-STATE STRUCTURES
Heterocycles | Phosphorus | CRYSTAL-STRUCTURES | Chalcogens | PHOSPHAZANE OLIGOMERS | CHEMISTRY, INORGANIC & NUCLEAR | HETEROMETALLIC COMPLEXES | REVERSIBLE CONVERSION | Hydrogen bonds | TRANS ISOMERS | CYCLODIPHOSPHAZANE | MOLECULAR-STRUCTURES | Selenium | ETHENE POLYMERIZATION | 1ST STRUCTURAL-CHARACTERIZATION | SOLID-STATE STRUCTURES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At...
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Journal of Biomolecular Structure and Dynamics, ISSN 0739-1102, 2019, pp. 1 - 15
NAD(P)H: quinone oxidoreductase 1 (NQO1) inhibitors are proved as promising therapeutic agents against cancer. This study is to determine potent...
NQO1 | virtual screening | 3D-QSAR | pharmacophore modeling | induced fit docking (IFD) | MDS | cancer and MM/GBSA
NQO1 | virtual screening | 3D-QSAR | pharmacophore modeling | induced fit docking (IFD) | MDS | cancer and MM/GBSA
Journal Article
Archives of Disease in Childhood - Fetal and Neonatal Edition, ISSN 1359-2998, 06/2011, Volume 96, Issue Suppl 1, pp. Fa29 - Fa29
Research into treatment of stroke and neonatal hypoxic-ischaemic (HI) insult has been beset by high variability in clinical and histopathology outcome despite...
Journal Article
Free Radical Biology and Medicine, ISSN 0891-5849, 11/2017, Volume 112, pp. 55 - 56
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9771, pp. 1096 - 1101.e2
Summary Background The aim of the CRASH-2 trial was to assess the effects of early administration of tranexamic acid on death, vascular occlusive events, and...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | COAGULOPATHY | Antifibrinolytic Agents - therapeutic use | Hemorrhage - drug therapy | Time Factors | Humans | Wounds and Injuries - complications | Hemorrhage - mortality | Adult | Logistic Models | Tranexamic Acid - therapeutic use | Clinical trials | Data collection | Blood pressure | Statistical analysis | Acids | Charitable foundations
Internal Medicine | MEDICINE, GENERAL & INTERNAL | COAGULOPATHY | Antifibrinolytic Agents - therapeutic use | Hemorrhage - drug therapy | Time Factors | Humans | Wounds and Injuries - complications | Hemorrhage - mortality | Adult | Logistic Models | Tranexamic Acid - therapeutic use | Clinical trials | Data collection | Blood pressure | Statistical analysis | Acids | Charitable foundations
Journal Article